

# BRCC3 antibody - C-terminal region

Rabbit Polyclonal Antibody

Catalog # AI14755

## Product Information

<b>Application</b>	WB
<b>Primary Accession</b>	<a href="#">P46736</a>
<b>Other Accession</b>	<a href="#">NM_024332</a> , <a href="#">NP_077308</a>
<b>Reactivity</b>	Human, Mouse, Rat, Rabbit, Zebrafish, Pig, Guinea Pig, Horse, Bovine
<b>Predicted</b>	Human, Mouse, Rat, Rabbit, Pig, Chicken, Guinea Pig, Horse, Bovine
<b>Host</b>	Rabbit
<b>Clonality</b>	Polyclonal
<b>Calculated MW</b>	36072

## Additional Information

<b>Gene ID</b>	79184
<b>Alias Symbol</b>	BRCC36, C6.1A, CXorf53, RP11-143H17.2
<b>Other Names</b>	Lys-63-specific deubiquitinase BRCC36, 3.4.19.-, BRCA1-A complex subunit BRCC36, BRCA1/BRCA2-containing complex subunit 3, BRCA1/BRCA2-containing complex subunit 36, BRISC complex subunit BRCC36, BRCC3, BRCC36, C6.1A, CXorf53
<b>Format</b>	Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
<b>Reconstitution &amp; Storage</b>	Add 50 ul of distilled water. Final anti-BRCC3 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.
<b>Precautions</b>	BRCC3 antibody - C-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

## Protein Information

<b>Name</b>	BRCC3
<b>Synonyms</b>	BRCC36, C6.1A, CXorf53
<b>Function</b>	Metalloprotease that specifically cleaves 'Lys-63'-linked polyubiquitin chains (PubMed: <a href="#">19214193</a> , PubMed: <a href="#">20656690</a> , PubMed: <a href="#">24075985</a> , PubMed: <a href="#">26344097</a> ). Does not have activity toward 'Lys- 48'-linked polyubiquitin chains (PubMed: <a href="#">19214193</a> , PubMed: <a href="#">20656690</a> , PubMed: <a href="#">24075985</a> , PubMed: <a href="#">26344097</a> ). Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones

H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs) (PubMed:[14636569](#), PubMed:[16707425](#), PubMed:[17525341](#), PubMed:[19202061](#), PubMed:[19261746](#), PubMed:[19261748](#), PubMed:[19261749](#)). In the BRCA1-A complex, it specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX, antagonizing the RNF8-dependent ubiquitination at double-strand breaks (DSBs) (PubMed:[20656690](#)). Catalytic subunit of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin in various substrates (PubMed:[20656690](#), PubMed:[24075985](#), PubMed:[26195665](#), PubMed:[26344097](#)). Mediates the specific 'Lys-63'-specific deubiquitination associated with the COP9 signalosome complex (CSN), via the interaction of the BRISC complex with the CSN complex (PubMed:[19214193](#)). The BRISC complex is required for normal mitotic spindle assembly and microtubule attachment to kinetochores via its role in deubiquitinating NUMA1 (PubMed:[26195665](#)). Plays a role in interferon signaling via its role in the deubiquitination of the interferon receptor IFNAR1; deubiquitination increases IFNAR1 activity by enhancing its stability and cell surface expression (PubMed:[24075985](#), PubMed:[26344097](#)). Acts as a regulator of the NLRP3 inflammasome by mediating deubiquitination of NLRP3, leading to NLRP3 inflammasome assembly (By similarity). Down- regulates the response to bacterial lipopolysaccharide (LPS) via its role in IFNAR1 deubiquitination (PubMed:[24075985](#)). Deubiquitinates HDAC1 and PWWP2B leading to their stabilization (By similarity).

#### Cellular Location

Nucleus. Cytoplasm. Cytoplasm, cytoskeleton, spindle pole Note=Localizes at sites of DNA damage at double-strand breaks (DSBs) (PubMed:20656690, PubMed:26344097). Interaction with ABRAXAS2 retains BRCC3 in the cytoplasm (PubMed:20656690).


#### Tissue Location

Heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Aberrantly expressed in the vast majority of breast tumors.

## References

Kenwrick S.,et al.Hum. Mol. Genet. 1:179-186(1992).  
Fisch P.,et al.Oncogene 8:3271-3276(1993).  
Dong Y.,et al.Mol. Cell 12:1087-1099(2003).  
Ota T.,et al.Nat. Genet. 36:40-45(2004).  
Ross M.T.,et al.Nature 434:325-337(2005).

## Images



WB Suggested Anti-BRCC3 Antibody Titration: 1.0 µg/ml  
Positive Control: MDA-MB-435S Whole Cell